300702 天宇股份
已收盘 07-19 15:00:00
资讯
新帖
简况
天宇股份(300702.SZ)尼可地尔原料药通过CDE审评
智通财经 · 07-18 16:56
天宇股份(300702.SZ)尼可地尔原料药通过CDE审评
天宇股份(300702)股东林洁质押1550万股,占总股本4.45%
证券之星 · 07-09
天宇股份(300702)股东林洁质押1550万股,占总股本4.45%
天宇股份(300702)7月8日主力资金净买入49.36万元
证券之星 · 07-08
天宇股份(300702)7月8日主力资金净买入49.36万元
天宇股份最新公告:全资子公司3款药品获得批准
证券之星 · 07-05
天宇股份最新公告:全资子公司3款药品获得批准
天宇股份(300702.SZ)子公司诺得药业收到多项药品注册证书
智通财经 · 07-05
天宇股份(300702.SZ)子公司诺得药业收到多项药品注册证书
天宇股份最新公告:向不特定对象发行可转换债券方案到期失效
证券之星 · 07-03
天宇股份最新公告:向不特定对象发行可转换债券方案到期失效
天宇股份最新公告:子公司恩格列净片获得药品注册证书
证券之星 · 06-25
天宇股份最新公告:子公司恩格列净片获得药品注册证书
天宇股份(300702.SZ)子公司取得恩格列净片药品注册证书
智通财经网 · 06-25
天宇股份(300702.SZ)子公司取得恩格列净片药品注册证书
高血压概念盘中跳水,天宇股份跌0.05%
自选股智能写手 · 06-19
高血压概念盘中跳水,天宇股份跌0.05%
天宇股份(300702)6月18日主力资金净卖出106.19万元
证券之星 · 06-18
天宇股份(300702)6月18日主力资金净卖出106.19万元
天宇股份(300702.SZ):达格列净原料药通过CDE审评
港股那点事 · 06-13
天宇股份(300702.SZ):达格列净原料药通过CDE审评
天宇股份最新公告:达格列净原料药通过CDE审评
证券之星 · 06-13
天宇股份最新公告:达格列净原料药通过CDE审评
天宇股份最新公告:恩格列净原料药通过CDE审评
证券之星 · 05-31
天宇股份最新公告:恩格列净原料药通过CDE审评
天宇股份(300702.SZ):恩格列净原料药通过CDE审评
智通财经 · 05-31
天宇股份(300702.SZ):恩格列净原料药通过CDE审评
天宇股份(300702.SZ)2023年年度权益分派:每10股派0.5元 6月5日股权登记
智通财经 · 05-30
天宇股份(300702.SZ)2023年年度权益分派:每10股派0.5元 6月5日股权登记
高血压概念盘中跳水,天宇股份跌1.30%
自选股智能写手 · 05-21
高血压概念盘中跳水,天宇股份跌1.30%
天宇股份:公司合成生物学的技术平台正在建设中,目前已与高校达成合作共同开展生物催化相关研究
证券之星 · 05-11
天宇股份:公司合成生物学的技术平台正在建设中,目前已与高校达成合作共同开展生物催化相关研究
天宇股份(300702.SZ)子公司两款药品获国家药监局批准
智通财经 · 05-09
天宇股份(300702.SZ)子公司两款药品获国家药监局批准
天宇股份(300702)5月8日主力资金净卖出178.62万元
证券之星 · 05-08
天宇股份(300702)5月8日主力资金净卖出178.62万元
天宇股份(300702.SZ):沙库巴曲缬沙坦钠片取得药品注册证书
智通财经 · 04-30
天宇股份(300702.SZ):沙库巴曲缬沙坦钠片取得药品注册证书
加载更多
公司概况
公司名称:
浙江天宇药业股份有限公司
所属行业:
医药制造业
上市日期:
2017-09-19
主营业务:
浙江天宇药业股份有限公司主营业务为化学原料药及中间体的研发、生产和销售。公司产品主要包括抗高血压药物原料药及中间体、抗哮喘药物原料药及中间体、抗病毒药物中间体等。公司目前已形成了以沙坦类药物原料药及中间体产品为主,抗病毒药物中间体及CMO业务多元发展的业务格局,是全球规模最大、品种最为齐全的沙坦类抗高血压药物原料药及中间体生产企业之一。
发行价格:
22.41
{"stockData":{"symbol":"300702","market":"SZ","secType":"STK","nameCN":"天宇股份","latestPrice":16.64,"timestamp":1721372619000,"preClose":16.88,"halted":0,"volume":1306200,"delay":0,"floatShares":211000000,"shares":348000000,"eps":-0.093,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.24,"latestTime":"07-19 15:00:00","open":16.86,"high":16.86,"low":16.54,"amount":21795000,"amplitude":0.019,"askPrice":16.64,"askSize":3,"bidPrice":16.63,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-0.093,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721611800000},"adr":0,"adjPreClose":16.88,"symbolType":"stock","openAndCloseTimeList":[[1721352600000,1721359800000],[1721365200000,1721372400000]],"highLimit":18.57,"lowLimit":15.19,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":347977159,"pbRate":1.68,"roa":"--","roe":"1.15%","epsLYR":0.08,"committee":-0.684807,"marketValue":5790000000,"floatMarketCap":3514000000,"peRate":-178.924727,"changeRate":-0.0142,"turnoverRate":0.0062,"status":1},"requestUrl":"/m/hq/s/300702","defaultTab":"news","newsList":[{"id":"2452172787","title":"天宇股份(300702.SZ)尼可地尔原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2452172787","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452172787?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:56","pubTimestamp":1721292967,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)公告,公司尼可地尔原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。尼可地尔片可用于抗心绞痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702","BK0239","CDE","BK4017"],"gpt_icon":0},{"id":"2450047082","title":"天宇股份(300702)股东林洁质押1550万股,占总股本4.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450047082","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450047082?lang=zh_cn&edition=full","pubTime":"2024-07-09 21:24","pubTimestamp":1720531491,"startTime":"0","endTime":"0","summary":"证券之星消息,天宇股份7月9日公开信息显示,股东林洁向中信证券股份有限公司合计质押1550.0万股,占总股本4.45%。质押详情见下表:截止本公告日,股东林洁已累计质押股份2962.0万股,占其持股总数的24.27%,股东屠勇军已累计质押股份2050.0万股,占其持股总数的35.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070900048618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2449740857","title":"天宇股份(300702)7月8日主力资金净买入49.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449740857","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449740857?lang=zh_cn&edition=full","pubTime":"2024-07-08 15:29","pubTimestamp":1720423799,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月8日收盘,天宇股份报收于16.28元,下跌4.74%,换手率0.89%,成交量1.88万手,成交额3097.2万元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:天宇股份2024年一季报显示,公司主营收入6.89亿元,同比下降11.29%;归母净利润4051.73万元,同比下降59.58%;扣非净利润5251.51万元,同比下降42.72%;负债率43.31%,投资收益-2637.71万元,财务费用-265.13万元,毛利率35.33%。天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800014473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2449664572","title":"天宇股份最新公告:全资子公司3款药品获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2449664572","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449664572?lang=zh_cn&edition=full","pubTime":"2024-07-05 19:41","pubTimestamp":1720179662,"startTime":"0","endTime":"0","summary":"天宇股份公告,全资子公司诺得药业于近日收到国家药监局核准签发的关于叶酸片、坎地氢噻片、达格列净片的《药品注册证书》。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500042765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2449062265","title":"天宇股份(300702.SZ)子公司诺得药业收到多项药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449062265","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449062265?lang=zh_cn&edition=full","pubTime":"2024-07-05 19:33","pubTimestamp":1720179219,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)公告,公司全资子公司浙江诺得药业有限公司(简称“诺得药业”)于近日收到国家药品监督管理局核准签发的关于叶酸片、坎地氢噻片、达格列净片的《药品注册证书》。公告显示,叶酸片一种维生素类药,用于各种原因引起的叶酸缺乏及叶酸缺乏所致的巨幼红细胞贫血;慢性溶血性贫血所致的叶酸缺乏;对于计划怀孕且已知有风险的妇女,可预防胎儿神经管缺陷。坎地氢噻片用于治疗高血压。达格列净片用于2型糖尿病成人患者、心力衰竭成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2448172667","title":"天宇股份最新公告:向不特定对象发行可转换债券方案到期失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2448172667","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448172667?lang=zh_cn&edition=full","pubTime":"2024-07-03 17:40","pubTimestamp":1719999604,"startTime":"0","endTime":"0","summary":"天宇股份公告,截至本公告披露日,公司本次向不特定对象发行可转换债券方案已到期自动失效。公司本次向不特定对象发行可转换债券方案的失效,不会对公司生产经营造成重大影响,未来公司将根据经营发展战略及资金需求情况,制定相应的资本市场融资计划,如公司未来有新的再融资计划,将根据相关规定及时履行相应审议程序及信息披露义务,敬请广大投资者注意投资风险。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070300037258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2446774819","title":"天宇股份最新公告:子公司恩格列净片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446774819","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446774819?lang=zh_cn&edition=full","pubTime":"2024-06-25 19:00","pubTimestamp":1719313259,"startTime":"0","endTime":"0","summary":"天宇股份公告,公司全资子公司浙江诺得药业有限公司近日收到国家药监局核准签发的关于恩格列净片的《药品注册证书》。恩格列净片是一种钠葡萄糖共转运体2(SGLT-2)抑制剂,用于治疗2型糖尿病和心力衰竭成人患者。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500035790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2446815432","title":"天宇股份(300702.SZ)子公司取得恩格列净片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446815432","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446815432?lang=zh_cn&edition=full","pubTime":"2024-06-25 18:33","pubTimestamp":1719311627,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告,公司全资子公司浙江诺得药业有限公司(简称“诺得...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2444549416","title":"高血压概念盘中跳水,天宇股份跌0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444549416","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444549416?lang=zh_cn&edition=full","pubTime":"2024-06-19 09:40","pubTimestamp":1718761230,"startTime":"0","endTime":"0","summary":"06月19日,高血压概念盘中跳水,截至09点40分,高血压概念整体指数下跌0.55%,报981.820点。从个股上来看,该概念的成分股中,天宇股份跌0.05%,恒瑞医药、信立泰、福元医药跌幅居前。从资金上来看,截止发稿,高血压概念主力净流入为-9.63万,其中恒瑞医药受到资金热捧,主力净流入401.22万;拉长时间线来看,该板块近20日主力资金净流入-5.03亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240619094030af8e25d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240619094030af8e25d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","LU1064131003.USD","LU1328615791.USD","300702","LU0405327494.USD","BK0196","BK0060","600276","BK0012","LU0405327148.USD","BK0183","LU1064130708.USD","BK0028","LU2148510915.USD","BK0239"],"gpt_icon":0},{"id":"2444172050","title":"天宇股份(300702)6月18日主力资金净卖出106.19万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444172050","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444172050?lang=zh_cn&edition=full","pubTime":"2024-06-18 15:25","pubTimestamp":1718695550,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月18日收盘,天宇股份报收于18.55元,下跌1.49%,换手率0.73%,成交量1.54万手,成交额2869.61万元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:天宇股份2024年一季报显示,公司主营收入6.89亿元,同比下降11.29%;归母净利润4051.73万元,同比下降59.58%;扣非净利润5251.51万元,同比下降42.72%;负债率43.31%,投资收益-2637.71万元,财务费用-265.13万元,毛利率35.33%。天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061800023662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2443504325","title":"天宇股份(300702.SZ):达格列净原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2443504325","media":"港股那点事","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443504325?lang=zh_cn&edition=full","pubTime":"2024-06-13 19:23","pubTimestamp":1718277780,"startTime":"0","endTime":"0","summary":"格隆汇6月13日丨天宇股份(300702.SZ)公布,达格列净原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。达格列净片可用于治疗2型糖尿病。\n\nMACD金叉信号形成,这些股涨势不错!\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/bxjj/2024-06-13/doc-inayqwqe9271156.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2024-06-13/doc-inayqwqe9271156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK4017","CDE","300702"],"gpt_icon":0},{"id":"2443501629","title":"天宇股份最新公告:达格列净原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2443501629","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443501629?lang=zh_cn&edition=full","pubTime":"2024-06-13 19:10","pubTimestamp":1718277001,"startTime":"0","endTime":"0","summary":"天宇股份公告,公司达格列净原料药于近日通过国家药品监督管理局药品审评中心审评。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300035346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2439897968","title":"天宇股份最新公告:恩格列净原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2439897968","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439897968?lang=zh_cn&edition=full","pubTime":"2024-05-31 17:20","pubTimestamp":1717147210,"startTime":"0","endTime":"0","summary":"天宇股份公告,公司恩格列净原料药于近日通过国家药品监督管理局药品审评中心(简称“CDE”)审评。恩格列净片可用于治疗2型糖尿病。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053100033958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2439957475","title":"天宇股份(300702.SZ):恩格列净原料药通过CDE审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2439957475","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439957475?lang=zh_cn&edition=full","pubTime":"2024-05-31 17:08","pubTimestamp":1717146512,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)发布公告,公司恩格列净原料药于近日通过国家药品监督管理局药品审评中心(“CDE”)审评。根据CDE网站公示,截止公告日,该原料药除公司外,国内获得CDE技术审评通过的厂家有18家。公司恩格列净原料药未完成GMP符合性检查,目前正在准备向浙江省药品监督管理局申请对该品种进行GMP符合性检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1129045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300702","CDE","BK4017"],"gpt_icon":0},{"id":"2439964946","title":"天宇股份(300702.SZ)2023年年度权益分派:每10股派0.5元 6月5日股权登记","url":"https://stock-news.laohu8.com/highlight/detail?id=2439964946","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439964946?lang=zh_cn&edition=full","pubTime":"2024-05-30 20:51","pubTimestamp":1717073519,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)发布公告,公司2023年年度权益分派方案为:以公司现有总股本剔除已回购股份为基数,向全体股东每10股派0.5元人民币现金(含税),本次权益分派股权登记日为:2024年6月5日,除权除息日为:2024年6月6日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1128667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2437469274","title":"高血压概念盘中跳水,天宇股份跌1.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437469274","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437469274?lang=zh_cn&edition=full","pubTime":"2024-05-21 14:22","pubTimestamp":1716272522,"startTime":"0","endTime":"0","summary":"05月21日,高血压概念盘中跳水,截至14点21分,高血压概念整体指数下跌1.02%,报1041.340点。从个股上来看,该概念的成分股中,天宇股份跌1.30%,方盛制药、华海药业、恒瑞医药跌幅居前。从资金上来看,截止发稿,高血压概念主力净流入为-1603.20万,其中恒瑞医药受到资金热捧,主力净流入2039.20万;拉长时间线来看,该板块近20日主力资金净流入-7.95亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052114220287e88db2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052114220287e88db2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","LU0405327148.USD","BK0188","BK0060","300702","BK0183","LU1328615791.USD","BK0196","BK0239","LU2148510915.USD","LU0405327494.USD","LU1064130708.USD","LU1064131003.USD","BK0012","BK0028"],"gpt_icon":0},{"id":"2434472998","title":"天宇股份:公司合成生物学的技术平台正在建设中,目前已与高校达成合作共同开展生物催化相关研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2434472998","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434472998?lang=zh_cn&edition=full","pubTime":"2024-05-11 16:02","pubTimestamp":1715414528,"startTime":"0","endTime":"0","summary":"证券之星消息,天宇股份(300702)05月11日在投资者关系平台上答复投资者关心的问题。投资者:董秘你好,请问一下公司在合成生物方面有那些技术储备呢天宇股份董秘:感谢您的关注!公司合成生物学的技术平台正在建设中,目前已与高校达成合作共同开展生物催化相关研究。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051100017724.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2434946064","title":"天宇股份(300702.SZ)子公司两款药品获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2434946064","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434946064?lang=zh_cn&edition=full","pubTime":"2024-05-09 17:59","pubTimestamp":1715248772,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份 发布公告,公司全资子公司浙江诺得药业有限公司于近日收到国家药品监督管理局核准签发的关于二甲双胍维格列汀片(Ⅲ)、复方聚乙二醇电解质散(Ⅲ)的《药品注册证书》。公司产品二甲双胍维格列汀片(Ⅲ)、复方聚乙二醇电解质散(Ⅲ)获得国家药监局批件后可在境内生产、销售,进一步丰富了公司的制剂品种,有望增加公司制剂业务收入,有助于提升公司产品的市场竞争力,对公司的经营业绩产生积极的影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2433713607","title":"天宇股份(300702)5月8日主力资金净卖出178.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433713607","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433713607?lang=zh_cn&edition=full","pubTime":"2024-05-08 15:21","pubTimestamp":1715152901,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月8日收盘,天宇股份报收于20.56元,上涨2.24%,换手率1.98%,成交量4.18万手,成交额8521.9万元。近5日资金流向一览见下表:该股主要指标及行业内排名如下:天宇股份2024年一季报显示,公司主营收入6.89亿元,同比下降11.29%;归母净利润4051.73万元,同比下降59.58%;扣非净利润5251.51万元,同比下降42.72%;负债率43.31%,投资收益-2637.71万元,财务费用-265.13万元,毛利率35.33%。天宇股份主营业务:化学原料药及中间体的研发、注册、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800021278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2431392392","title":"天宇股份(300702.SZ):沙库巴曲缬沙坦钠片取得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2431392392","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431392392?lang=zh_cn&edition=full","pubTime":"2024-04-30 17:32","pubTimestamp":1714469574,"startTime":"0","endTime":"0","summary":"智通财经APP讯,天宇股份(300702.SZ)公告,公司全资子公司浙江诺得药业有限公司(简称“诺得药业”)于近日收到国家药品监督管理局核准签发的关于沙库巴曲缬沙坦钠片的《药品注册证书》。沙库巴曲缬沙坦钠片是治疗慢性心力衰竭药物,用于射血分数降低的慢性心力衰竭的成人患者和用于治疗原发性高血压。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-09-19","address":"浙江省台州市黄岩区黄岩江口化工开发区","stockEarnings":[{"period":"1week","weight":-0.0376},{"period":"1month","weight":-0.0947},{"period":"3month","weight":0.0167},{"period":"6month","weight":-0.0889},{"period":"1year","weight":-0.287},{"period":"ytd","weight":-0.2316}],"companyName":"浙江天宇药业股份有限公司","boardCode":"AI0027","perCapita":"13168股","boardName":"医药制造业","registeredCapital":"34797万元","compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0118},{"period":"3month","weight":-0.0271},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":0.0025}],"survey":" 浙江天宇药业股份有限公司主营业务为化学原料药及中间体的研发、生产和销售。公司产品主要包括抗高血压药物原料药及中间体、抗哮喘药物原料药及中间体、抗病毒药物中间体等。公司目前已形成了以沙坦类药物原料药及中间体产品为主,抗病毒药物中间体及CMO业务多元发展的业务格局,是全球规模最大、品种最为齐全的沙坦类抗高血压药物原料药及中间体生产企业之一。","serverTime":1721442583319,"listedPrice":22.41,"stockholders":"16036人(较上一季度增加0.44%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天宇股份,300702,天宇股份股票,天宇股份股票老虎,天宇股份股票老虎国际,天宇股份行情,天宇股份股票行情,天宇股份股价,天宇股份股市,天宇股份股票价格,天宇股份股票交易,天宇股份股票购买,天宇股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}